Supernus Pharmaceuticals (SUPN) Receivables - Net (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Receivables - Net data on file, last reported at $182.2 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 25.09% year-over-year to $182.2 million in Q1 2026; TTM through Mar 2026 was $182.2 million, a 25.09% increase from a year earlier, with the FY2025 full-year figure at $187.8 million, up 32.18% from the prior year.
• Receivables - Net for Q1 2026 stood at $182.2 million, down from $187.8 million in the prior quarter.
• Over the last five years, Receivables - Net for SUPN reached as high as $187.8 million in Q4 2025 and fell as low as $136.6 million in Q2 2023.
• Historically, Receivables - Net has averaged $154.4 million across 5 years, with a median of $146.7 million in 2024.
• Across the five-year window, Receivables - Net slipped 13.61% in 2023 and soared 32.18% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $165.5 million in 2022, then declined by 14.34% to $141.8 million in 2023, then advanced by 0.22% to $142.1 million in 2024, then jumped by 32.18% to $187.8 million in 2025, then declined by 2.99% to $182.2 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $182.2 million in Q1 2026, $187.8 million in Q4 2025, and $171.3 million in Q3 2025.